Please login to the form below
ozanimod
This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.
Celgene to launch five new products through to 2020
The five blockbusters-in-waiting are multiple sclerosis therapy ozanimod – which has been delayed by the FDA’s refusal to accept the company’s regulatory filing earlier this year – fedratinib for
Latest news
-
Novartis files for approval of MS drug in EU, US
Another potential rival – Celgene’s ozanimod – hit the buffers after the FDA refused to accept the company’s regulatory filing earlier this year.
-
Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome read to leap into future
The news is very welcome for Celgene, which has suffered numerous setbacks in recent months, including the FDA refusing to accept the filing of ozanimod in February.
-
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
Smith looked to have paid the price for some costly slip-ups in recent months, most notably the FDA’s refused to review Celgene’s multiple sclerosis drug, ozanimod.
-
Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
This looks like Smith has paid the price for some costly slip-ups in recent months, most notably the FDA’s refused to review Celgene’s multiple sclerosis drug, ozanimod.
-
Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more
new drugs, multiple sclerosis candidate ozanimod - and all because the company had failed to provide adequate non-clinical and clinical pharmacology data in its dossier.
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Pharma deals in July 2015
Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Medical Writers
-
Competitive Salary and Benefits
-
New Business Director - PR
-
Competitive Salary and benefits
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
- Events Manager – Med Comms – Surrey
-
Salary TBC
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Senior Medical Writer
-
Competitive Salary
- Senior Systematic Review Analyst - Oxford
-
Negotiable
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Senior Medical Writer
-
Great salary and benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Senior Account Manager
-
Negotiable
- Director, Market Access / HEOR - North-West
-
Negotiable
-
Consumer Health Account Director
-
Circa £60, 000 Gym and More
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Senior Account Executive, London, Medical Communications
-
Excellent package
Subscribe to our email news alerts
- Healthcare sector bullish, despite political uncertainty
- Bioprocessing Analytics Equipment Market is anticipated to register a CAGR of 4.5% over the forecast period 2028
- Behavioural Health Market is expected to expand at 3.4% CAGR over the forecast period 2018-2028.
- Prurigo Nodularis Treatment Market is poised to expand at 3.4% CAGR over the forecast period of 2018–2028
- Biologic Excipients Market is projected to register a CAGR of 3.6% over the forecast period 2018-2028
- Bone Screw System Market to reach a market value of US$ 1,963 Mn in 2028
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
- Nudge-nudge, think-think
- Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
- Quality in Care Diabetes 2018: the best in innovative diabetes care
- Awards highlight new evidence-based approaches to improving care...
Quick links
Infographics
